Genomic technology applied to pharmacological traits

JAMA

Volumn 306, Issue 6, 2011, Pages 652-653

  Yang, Jun J ^a   Plenge, Robert M ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOPIDOGREL; DNA; INOSINE TRIPHOSPHATE; METFORMIN; RIBAVIRIN; WARFARIN;

DRUG EFFICACY; DRUG TOXICITY; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN GENOME; NOTE; PHARMACOGENOMICS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; GENETICS; LABORATORY DIAGNOSIS; PHARMACOGENETICS; PHENOTYPE;

DNA; DRUG TOXICITY; FALSE POSITIVE REACTIONS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80051564495     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1125     Document Type: Note

References (10)

1. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061-1073.
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144-1153.
3. Zhou K, Bellenguez C, Spencer CC, et al; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC Investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117-120.
4. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
5. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405-408.
6. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
7. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA. 2008;299(11):1335-1344. (Pubitemid 351439079)
8. Mardis ER. A decade's perspective on DNA sequencing technology. Nature. 2011;470(7333):198-203.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. (Pubitemid 38637993)
10. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther. 2011;89(3):379-386.